Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SGEN [NASD]
Seagen Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E46.30 EPS (ttm)3.29 Insider Own0.70% Shs Outstand179.11M Perf Week-3.19%
Market Cap27.45B Forward P/E339.76 EPS next Y0.45 Insider Trans-29.01% Shs Float132.56M Perf Month-6.16%
Income613.70M PEG- EPS next Q-0.61 Inst Own91.50% Short Float2.29% Perf Quarter-7.80%
Sales2.18B P/S12.62 EPS this Y451.20% Inst Trans2.71% Short Ratio2.78 Perf Half Y-1.01%
Book/sh19.47 P/B7.84 EPS next Y120.80% ROA21.80% Target Price195.20 Perf Year33.98%
Cash/sh14.22 P/C10.73 EPS next 5Y- ROE26.30% 52W Range90.57 - 213.94 Perf YTD-12.90%
Dividend- P/FCF35.46 EPS past 5Y41.20% ROI17.10% 52W High-28.69% Beta0.95
Dividend %- Quick Ratio7.60 Sales past 5Y45.20% Gross Margin90.00% 52W Low68.43% ATR7.05
Employees2092 Current Ratio7.90 Sales Q/Q107.50% Oper. Margin27.40% RSI (14)36.75 Volatility3.28% 4.57%
OptionableYes Debt/Eq0.00 EPS Q/Q496.10% Profit Margin28.20% Rel Volume1.18 Prev Close151.11
ShortableYes LT Debt/Eq0.00 EarningsFeb 11 AMC Payout0.00% Avg Volume1.10M Price152.55
Recom2.10 SMA20-6.92% SMA50-12.93% SMA200-11.53% Volume1,294,877 Change0.95%
Feb-01-21Downgrade RBC Capital Mkts Outperform → Sector Perform $188 → $186
Jan-15-21Upgrade BofA Securities Neutral → Buy $215
Sep-22-20Reiterated Stifel Hold $145 → $165
Aug-24-20Resumed Berenberg Buy $187
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-01-20Upgrade Guggenheim Neutral → Buy
May-01-20Reiterated Needham Buy $157 → $163
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Feb-27-21 09:23AM  
15 Fastest Growing Biotech Companies in the US
Insider Monkey
Feb-24-21 08:00AM  
Seagen to Present at the Cowen 41st Annual Healthcare Conference
Business Wire
Feb-18-21 08:00AM  
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Business Wire
08:00AM  
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
PR Newswire
Feb-15-21 05:41AM  
Announcing: Seagen (NASDAQ:SGEN) Stock Soared An Exciting 445% In The Last Five Years
Simply Wall St.
Feb-12-21 02:15PM  
Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
Business Wire
02:15PM  
Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
Business Wire
02:15PM  
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
PR Newswire
02:15PM  
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
PR Newswire
10:28AM  
Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
Zacks
06:45AM  
European Commission Approves Seagens TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Business Wire
05:31AM  
Seattle Genetics (SGEN) Q4 2020 Earnings Call Transcript
Motley Fool
Feb-11-21 05:45PM  
Seattle Genetics (SGEN) Q4 Earnings and Revenues Top Estimates
Zacks
04:02PM  
Seagen Reports Fourth Quarter and Full Year 2020 Financial Results
Business Wire
02:30PM  
Seagen Inc. to Host Earnings Call
ACCESSWIRE
Feb-10-21 04:05PM  
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Business Wire
Jan-07-21 08:00AM  
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
Business Wire +5.76%
Dec-30-20 12:04PM  
Merck Had a Disappointing 2020. Why Its Strategy Could Pay Off in 2021.
Barrons.com
Dec-16-20 08:00AM  
Seagen to Present at the J.P. Morgan Healthcare Conference
Business Wire
03:18AM  
Is Seagen Inc. (NASDAQ:SGEN) Popular Amongst Institutions?
Simply Wall St.
Dec-11-20 07:23AM  
Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Business Wire
Dec-08-20 08:00AM  
Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium
Business Wire
Dec-07-20 10:00AM  
Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting
Business Wire
Nov-11-20 03:15AM  
These 23 stocks and ETFs will benefit from the 6 most important changes for stock-market investors under Biden
MarketWatch
Nov-09-20 08:00AM  
Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020
Business Wire
Nov-05-20 08:00AM  
Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting
Business Wire
Nov-03-20 08:57AM  
Were Hedge Funds Right About Warming Up To Seagen Inc. (SGEN)?
Insider Monkey
06:17AM  
Seagen Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Simply Wall St.
Nov-02-20 08:00AM  
Seagen to Host Virtual R&D Day on November 16, 2020
Business Wire
Oct-30-20 01:07PM  
Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut
Zacks -13.28%
06:01AM  
Seattle Genetics (SGEN) Q3 2020 Earnings Call Transcript
Motley Fool
Oct-29-20 06:05PM  
Seattle Genetics (SGEN) Q3 Earnings and Revenues Top Estimates
Zacks
04:02PM  
Seagen Reports Third Quarter 2020 Financial Results
Business Wire
Oct-28-20 08:00AM  
Seagen Announces Closing of $1.0 Billion Stock Sale to Merck
Business Wire
Oct-22-20 12:33PM  
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks
12:27PM  
Are Investors Undervaluing Seagen Inc. (NASDAQ:SGEN) By 21%?
Simply Wall St.
Oct-13-20 01:33PM  
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
Zacks
08:00AM  
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020
Business Wire
Oct-12-20 06:45AM  
Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Business Wire
06:45AM  
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
PR Newswire
Oct-08-20 08:00AM  
Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.
Business Wire
Oct-07-20 09:44AM  
Why Seattle Genetics Stock Jumped 24% in September
Motley Fool
Oct-05-20 11:13AM  
Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?
TheStreet.com
Oct-03-20 06:55AM  
Next Coronavirus Market Crash: Where to Invest $10,000
Motley Fool
Oct-01-20 12:42PM  
Seattle Genetics Hits New Highs and a Strategy Adjustment Is Needed
TheStreet.com
Sep-28-20 05:33PM  
Dow Jones Futures: Stock Market Rally Needs To Turn Up The Volume; Target, Adobe, Nvidia Lead Top Stocks In Buy Zones
Investor's Business Daily
Sep-24-20 07:33AM  
Seattle Genetics' Shares March Higher, Can It Continue?
Zacks
Sep-21-20 10:20AM  
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Business Wire
Sep-18-20 01:17PM  
Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival
Zacks
12:38PM  
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
Zacks
06:45AM  
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Business Wire
06:45AM  
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
PR Newswire
Sep-16-20 10:09AM  
Analysts Just Published A Bright New Outlook For Seattle Genetics, Inc.'s (NASDAQ:SGEN)
Simply Wall St.
09:47AM  
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
Zacks
Sep-15-20 12:53PM  
Seattle Genetics Up on Two New Oncology Deals With Merck
Zacks
09:51AM  
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
Zacks
Sep-14-20 07:01PM  
Jim Cramer: Is This Market Undervalued?
TheStreet.com +14.55%
05:40PM  
Merck Inks Multibillion-Dollar Deal With Seattle Genetics, Including Equity
Motley Fool
04:39PM  
Seattle Genetics Pact With Drug Giant Merck Sends SGEN Stock Soaring
Investor's Business Daily
04:34PM  
US STOCKS-Wall Street closes broadly higher on deal news, vaccine hopes
Reuters
04:00PM  
US STOCKS-Wall Street closes broadly higher on deal news, vaccine hopes
Reuters
03:55PM  
Analyst Report: Seattle Genetics, Inc.
Morningstar Research
01:41PM  
Merck To Buy $1B Seattle Genetics Stake For Oncology Collab
SmarterAnalyst
12:48PM  
US STOCKS-Wall Street climbs on mega mergers, vaccine hopes
Reuters
11:15AM  
Mercks Partnership With Seattle Genetics Is a Bet on a New Anticancer Strategy
Barrons.com
10:30AM  
How About That Merck and Seattle Genetics Deal?
TheStreet.com
09:55AM  
Merck Inks Up to $4.5 Billion Seattle Genetics Cancer Deal
Bloomberg
09:51AM  
Looking Into Seattle Genetics's Return On Capital Employed
Benzinga
09:45AM  
Dow Jones Today, Stocks Open Higher On Nvidia, Gilead, Oracle Merger News; Micron Pops On Upgrade
Investor's Business Daily
09:38AM  
Merck Takes Seattle Genetics Stake, Plans Cancer-Drug Venture
TheStreet.com
08:01AM  
Shares of Seattle Genetics jump as Merck makes up to $4.2 billion investment
MarketWatch
06:45AM  
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Business Wire
Sep-09-20 08:41PM  
Hedge Funds Never Been This Bullish On Seattle Genetics, Inc. (SGEN)
Insider Monkey
Sep-03-20 08:00AM  
Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Business Wire
Sep-02-20 02:12PM  
Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years
Simply Wall St.
Aug-29-20 11:32AM  
Seattle Genetics (SGEN) Down 10.2% Since Last Earnings Report: Can It Rebound?
Zacks
Aug-28-20 11:52AM  
Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo
Zacks
Aug-27-20 08:10AM  
Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)
Business Wire
08:00AM  
Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020
Business Wire
Aug-18-20 08:00AM  
Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors
Business Wire
Aug-12-20 08:00AM  
Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDAs Project Orbis Initiative
Business Wire
Aug-06-20 08:00AM  
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval
Business Wire
Jul-31-20 08:32PM  
Seattle Genetics (SGEN) Q2 2020 Earnings Call Transcript
Motley Fool
11:16AM  
Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales
Zacks
Jul-30-20 05:15PM  
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
Zacks
04:02PM  
Seattle Genetics Reports Second Quarter 2020 Financial Results
Business Wire
Jul-28-20 06:23AM  
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
Motley Fool
Jul-24-20 12:10PM  
Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation
Benzinga
Jul-23-20 12:33PM  
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks
Jul-19-20 08:58AM  
What Can We Learn About Seattle Genetics' (NASDAQ:SGEN) CEO Compensation?
Simply Wall St.
Jul-12-20 01:20PM  
Did Hedge Funds Make The Right Call On Seattle Genetics, Inc. (SGEN) ?
Insider Monkey
Jul-09-20 08:00AM  
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020
Business Wire
Jul-06-20 10:28AM  
Seattle Genetics' Adcetris Progresses Well Amid Competition
Zacks
Jul-03-20 10:03AM  
Why Seattle Genetics Shares Climbed 48.7% in the First Half
Motley Fool
Jun-30-20 07:41AM  
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
Benzinga
Jun-29-20 04:30PM  
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Business Wire
Jun-23-20 09:00PM  
Edited Transcript of SGEN.OQ earnings conference call or presentation 30-Apr-20 8:30pm GMT
Thomson Reuters StreetEvents
Jun-22-20 11:00AM  
Here's My Take on Seattle Genetics
TheStreet.com
08:12AM  
Dow Jones Futures Slash Losses: Stock Market Rally Faces Coronavirus Wave; Apple WWDC, Tesla News In Focus
Investor's Business Daily
Jun-18-20 08:00AM  
Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
Business Wire
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIU JEAN IGC/EVP, Leg AffairsFeb 17Option Exercise41.374,846200,46665,112Feb 18 08:48 PM
SIEGALL CLAY BPresident and CEOFeb 04Option Exercise15.4629,353453,797726,706Feb 05 08:00 PM
SIEGALL CLAY BPresident and CEOFeb 04Sale165.5729,3534,860,105715,209Feb 05 08:00 PM
LIU JEAN IGC/EVP, Leg AffairsJan 15Option Exercise35.955,000179,75065,266Jan 15 07:40 PM
LIU JEAN IGC/EVP, Leg AffairsJan 15Sale180.005,000900,00060,266Jan 15 07:40 PM
SIEGALL CLAY BPresident and CEOJan 07Option Exercise15.4629,353453,797719,687Jan 08 07:52 PM
SIEGALL CLAY BPresident and CEOJan 07Sale172.4429,3535,061,681715,209Jan 08 07:52 PM
SIMPSON TODD EChief Financial OfficerDec 18Option Exercise26.7134,773928,772152,436Dec 18 08:51 PM
SIMPSON TODD EChief Financial OfficerDec 18Sale200.0033,6696,733,800118,767Dec 18 08:51 PM
LIU JEAN IGC/EVP, Leg AffairsDec 16Option Exercise35.951,62458,38360,266Dec 16 07:41 PM
LIU JEAN IGC/EVP, Leg AffairsDec 14Option Exercise35.955,000179,75063,642Dec 16 07:41 PM
LIU JEAN IGC/EVP, Leg AffairsDec 14Sale195.865,000979,31658,642Dec 16 07:41 PM
SIEGALL CLAY BPresident and CEODec 07Option Exercise15.4615,723243,078720,265Dec 08 07:33 PM
HIMES VAUGHN BChief Technical OfficerDec 07Option Exercise25.3612,761323,646199,590Dec 09 08:08 PM
HIMES VAUGHN BChief Technical OfficerDec 07Sale181.768,0001,454,041191,590Dec 09 08:08 PM
SIEGALL CLAY BPresident and CEODec 07Sale181.1415,7232,848,122715,209Dec 08 07:33 PM
SIEGALL CLAY BPresident and CEODec 04Option Exercise15.4621,732335,977730,117Dec 08 07:33 PM
SIEGALL CLAY BPresident and CEODec 04Sale179.4321,7323,899,386715,209Dec 08 07:33 PM
SIEGALL CLAY BPresident and CEODec 03Option Exercise15.4621,253328,571726,145Dec 04 07:18 PM
ROMP CHARLES REVP, CommercialDec 03Option Exercise39.157,666300,12451,743Dec 03 05:45 PM
ROMP CHARLES REVP, CommercialDec 03Sale179.307,6661,374,51444,077Dec 03 05:45 PM
SIEGALL CLAY BPresident and CEODec 03Sale179.2821,2533,810,144715,209Dec 04 07:18 PM
ROMP CHARLES REVP, CommercialDec 01Option Exercise39.156,000234,90050,077Dec 03 05:45 PM
ROMP CHARLES REVP, CommercialDec 01Sale179.096,0001,074,53944,077Dec 03 05:45 PM
GRYSKA DAVID WDirectorNov 19Option Exercise19.0215,000285,30052,719Nov 23 08:11 PM
GRYSKA DAVID WDirectorNov 19Sale173.7015,0002,605,52344,848Nov 23 08:11 PM
SIMPSON TODD EChief Financial OfficerNov 05Sale180.377,5091,354,383118,767Nov 09 07:25 PM
GRYSKA DAVID WDirectorNov 05Sale180.604,500812,69944,848Nov 06 07:53 PM
ROMP CHARLES REVP, CommercialNov 04Option Exercise41.7414,079587,70349,228Nov 06 07:34 PM
DANSEY ROGER DChief Medical OfficerNov 04Sale177.007,6611,356,020110,221Nov 05 09:38 PM
ROMP CHARLES REVP, CommercialNov 04Sale180.3714,0792,539,42044,077Nov 06 07:34 PM
LIPPMAN MARC EDirectorNov 03Option Exercise35.4762,7802,226,870144,432Nov 05 08:44 PM
ROMP CHARLES REVP, CommercialNov 03Option Exercise19.245,19799,97947,719Nov 04 08:23 PM
ROMP CHARLES REVP, CommercialNov 03Sale172.076,0611,042,93944,077Nov 04 08:23 PM
LIPPMAN MARC EDirectorNov 03Sale168.61142,09023,958,28752,338Nov 05 08:44 PM
WELCH DANIEL GDirectorNov 02Option Exercise25.2149,5001,247,65271,098Nov 04 08:51 PM
WELCH DANIEL GDirectorNov 02Sale166.1358,7509,760,26047,348Nov 04 08:51 PM
ROMP CHARLES REVP, CommercialNov 02Sale166.7713,0012,168,12944,941Nov 04 08:23 PM
LIU JEAN IGC/EVP, Leg AffairsSep 21Option Exercise36.779,954366,01958,642Sep 23 07:28 PM
LIU JEAN IGC/EVP, Leg AffairsSep 14Sale170.0011,6101,973,70048,688Sep 16 06:53 PM
HIMES VAUGHN BChief Technical OfficerSep 09Option Exercise15.468,000123,680194,829Sep 11 06:25 PM
HIMES VAUGHN BChief Technical OfficerSep 09Sale147.558,0001,180,385186,829Sep 11 06:25 PM
SIMPSON TODD EChief Financial OfficerSep 01Sale155.8612,0911,884,512126,276Sep 02 07:24 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale155.693,585558,164186,829Sep 02 07:25 PM
DANSEY ROGER DChief Medical OfficerAug 31Sale155.694,611717,906117,882Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 31Sale155.6914,3512,234,367715,209Sep 02 07:24 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale155.694,187651,892138,367Sep 02 07:24 PM
ROMP CHARLES REVP, CommercialAug 31Sale155.691,133176,40257,942Sep 02 07:25 PM
LIU JEAN IGC/EVP, Leg AffairsAug 31Sale155.693,648567,97260,298Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 21Option Exercise19.4210,299199,984729,560Aug 25 06:35 PM
ROMP CHARLES REVP, CommercialAug 18Sale158.174,027636,94159,075Aug 20 06:26 PM
SIEGALL CLAY BPresident and CEOAug 18Sale158.1727,0604,280,053719,261Aug 20 06:26 PM
SIMPSON TODD EChief Financial OfficerAug 18Sale158.179,2621,464,959142,554Aug 20 06:27 PM
HIMES VAUGHN BChief Technical OfficerAug 18Sale158.178,0541,273,892190,414Aug 20 06:23 PM
LIU JEAN IGC/EVP, Leg AffairsAug 18Sale158.176,8461,082,82363,946Aug 20 06:58 PM
DANSEY ROGER DChief Medical OfficerAug 17Sale157.7945071,006122,493Aug 17 09:40 PM
SIEGALL CLAY BPresident and CEOAug 10Option Exercise12.0028,475341,700729,955Aug 13 06:04 AM
SIEGALL CLAY BPresident and CEOAug 10Sale156.7428,4754,463,263718,339Aug 13 06:04 AM
SIMPSON TODD EChief Financial OfficerAug 03Sale165.7220,0003,314,418143,181Aug 05 07:14 PM
HIMES VAUGHN BChief Technical OfficerJul 17Option Exercise15.468,000123,680199,840Jul 21 07:48 PM
HIMES VAUGHN BChief Technical OfficerJul 17Sale179.428,0001,435,363191,840Jul 21 07:48 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.0028,472341,664734,660Jul 10 06:07 PM
SIEGALL CLAY BPresident and CEOJul 08Sale175.0828,4724,984,808718,339Jul 10 06:07 PM
ROMP CHARLES REVP, CommercialJul 02Sale167.49712119,25355,307Jul 07 06:34 PM
SIMPSON TODD EChief Financial OfficerJul 01Sale167.5811,5731,939,352163,181Jul 02 07:19 PM
LIU JEAN IGC/EVP, Leg AffairsJun 19Sale165.009,8771,629,70563,597Jun 22 07:46 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale158.892,162343,523109,608Jun 19 05:54 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale157.15838131,692111,770Jun 17 07:24 PM
DANSEY ROGER DChief Medical OfficerJun 15Sale157.154,984783,236112,608Jun 17 07:24 PM
SIEGALL CLAY BPresident and CEOJun 08Option Exercise12.0028,472341,664724,939Jun 10 06:57 PM
SIEGALL CLAY BPresident and CEOJun 08Sale148.7728,4724,235,807718,339Jun 10 06:57 PM
BAKER BROS. ADVISORS LPDirectorMay 15Sale160.001,750,000280,000,0004,082,851May 19 06:03 PM
ROMP CHARLES REVP, CommercialMay 12Option Exercise15.466,942107,32359,517May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 12Sale166.006,9421,152,37252,575May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 08Option Exercise15.466,942107,32359,517May 08 07:54 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.0028,472341,664728,603May 12 07:51 PM
SIEGALL CLAY BPresident and CEOMay 08Sale161.0128,4724,584,311718,339May 12 07:51 PM
ROMP CHARLES REVP, CommercialMay 08Sale163.026,9421,131,66752,575May 08 07:54 PM
BAKER BROS. ADVISORS LPDirectorMay 08Sale158.50500,00079,250,0004,230,539May 08 05:47 PM
DANSEY ROGER DChief Medical OfficerMay 07Option Exercise65.1111,912775,590129,145May 08 07:42 PM
DANSEY ROGER DChief Medical OfficerMay 07Sale164.5011,9121,959,526117,233May 08 07:42 PM
BAKER BROS. ADVISORS LPDirectorMay 07Sale164.41168,24427,660,9474,272,736May 08 05:47 PM
SIEGALL CLAY BPresident and CEOMay 06Sale165.2325,4024,197,062718,339May 07 07:59 PM
WELCH DANIEL GDirectorMay 06Sale164.7915,0002,471,91955,263May 07 07:59 PM
BAKER BROS. ADVISORS LPDirectorMay 06Sale165.05390,07264,379,4734,286,935May 08 05:47 PM
SIMPSON TODD EChief Financial OfficerMay 05Option Exercise22.1539,059865,277188,563May 06 06:32 PM
AKKARAJU SRINIVASDirectorMay 05Option Exercise20.068,500170,51048,668May 07 07:58 PM
ROMP CHARLES REVP, CommercialMay 05Sale166.185,056840,22652,575May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Sale162.9426,8674,377,596161,696May 06 06:32 PM
SIEGALL CLAY BPresident and CEOMay 05Sale166.0824,5984,085,341743,741May 07 07:59 PM
WELCH DANIEL GDirectorMay 05Sale166.7320,0003,334,64170,263May 07 07:59 PM
AKKARAJU SRINIVASDirectorMay 05Sale167.268,5001,421,71040,168May 07 07:58 PM
SIMPSON TODD EChief Financial OfficerMay 04Option Exercise12.0014,167170,004175,863May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Sale147.0014,1672,082,556161,696May 06 06:32 PM
LIPPMAN MARC EDirectorMay 04Sale152.031,000152,030130,313May 06 06:19 PM
BAKER BROS. ADVISORS LPDirectorApr 23Option Exercise12.7635,000446,60045,860,149Apr 24 04:25 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.0028,472341,664779,866Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOApr 08Sale120.0128,4723,416,814758,784Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOMar 09Option Exercise12.0028,472341,664768,581Mar 11 06:51 PM
SIEGALL CLAY BPresident and CEOMar 09Sale110.0928,4723,134,578758,784Mar 11 06:51 PM
open in yahoo | open in reuters | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.